The clonogenic growth of advanced breast tumour lesions adds no value to that of established clinical prognosticators for survival.

por Hug, V., Polyzos, A., Tucker, S., Thames, H.
Publicado 1993

Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer

por Kosmas, C, Tsavaris, N, Malamos, N, Stavroyianni, N, Gregoriou, A, Rokana, S, Polyzos, A
Publicado 2003

Multiple Autoimmune Propensity and B-Non-Hodgkin Lymphoma: Cause or Effect?

por Koumati, E., Palassopoulou, M., Matsouka, P., Polyzos, A., Dalekos, G. N., Zachou, K.
Publicado 2011

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours

por Kosmas, C, Tsavaris, N B, Polyzos, A, Malamos, N A, Katsikas, M, Antonopoulos, M J
Publicado 2000

Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon

por Gogas, H, Kefala, G, Bafaloukos, D, Frangia, K, Polyzos, A, Pectasides, D, Tsoutsos, D, Panagiotou, P, Ioannovich, J, Loukopoulos, D
Publicado 2002

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of pa...

por Souglakos, J, Ziras, N, Kakolyris, S, Boukovinas, I, Kentepozidis, N, Makrantonakis, P, Xynogalos, S, Christophyllakis, Ch, Kouroussis, Ch, Vamvakas, L, Georgoulias, V, Polyzos, A
Publicado 2012

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cance...

por Souglakos, J, Androulakis, N, Syrigos, K, Polyzos, A, Ziras, N, Athanasiadis, A, Kakolyris, S, Tsousis, S, Kouroussis, Ch, Vamvakas, L, Kalykaki, A, Samonis, G, Mavroudis, D, Georgoulias, V
Publicado 2006

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter random...

por Georgoulias, V, Agelidou, A, Syrigos, K, Rapti, A, Agelidou, M, Nikolakopoulos, J, Polyzos, A, Athanasiadis, A, Tselepatiotis, E, Androulakis, N, Kalbakis, K, Samonis, G, Mavroudis, D
Publicado 2005

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre,...

por Georgoulias, V, Kouroussis, C, Agelidou, A, Boukovinas, I, Palamidas, P, Stavrinidis, E, Polyzos, A, Syrigos, K, Veslemes, M, Toubis, M, Ardavanis, A, Tselepatiotis, E, Vlachonikolis, I
Publicado 2004

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancrea...

por Stathopoulos, G P, Syrigos, K, Aravantinos, G, Polyzos, A, Papakotoulas, P, Fountzilas, G, Potamianou, A, Ziras, N, Boukovinas, J, Varthalitis, J, Androulakis, N, Kotsakis, A, Samonis, G, Georgoulias, V
Publicado 2006